Diverse roles of GSK-3: Tumor promoter-tumor suppressor, target in cancer therapy

Advances in Biological Regulation

Volumn 54, Issue 1, 2014, Pages 176-196

  McCubrey, James A ^a   Davis, Nicole M ^a   Abrams, Stephen L ^a   Montalto, Giuseppe ^b,c   Cervello, Melchiorre ^c   Basecke, Jorg ^d,e   Libra, Massimo ^f   Nicoletti, Ferdinando ^f   Cocco, Lucio ^g   Martelli, Alberto M ^c,g   Steelman, Linda S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e Department of Hematology and Oncology   (Germany)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3;

ANIMAL; ARTICLE; CARCINOGENESIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENESIS; GENES, TUMOR SUPPRESSOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEOPLASMS;

EID: 84893427084     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.09.013     Document Type: Article

References (170)

1. Aguilar A., Saba J.D. Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 2012, 52:17-30.
2. Amar S., Belmaker R.H., Agam G. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des. 2011, 17:2264-2277.
3. Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013, 13:11-26.
4. Bachelder R.E., Yoon S.O., Franci C., de Herreros A.G., Mercurio A.M. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. JCell Biol 2005, 168:29-33.
5. Banerji V., Frumm S.M., Ross K.N., Li L.S., Schinzel A.C., Hahn C.K., et al. The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. JClin Invest 2012, 122:935-947.
6. Bankaitis V.A., Ile K.E., Nile A.H., Ren J., Ghosh R., Schaaf G. Thoughts on Sec14-like nanoreactors and phosphoinositide signaling. Adv Biol Regul 2012, 52:115-121.
7. Barker C.J., Berggren P.O. The pancreatic beta cell as a paradigm for advances in inositide research. Adv Biol Regul 2012, 52:361-368.
8. Bartkova J., Lukas J., Müller H., Lützhøft D., Strauss M., Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994, 57:353-361.
9. Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R., et al. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure 2001, 9:1143-1152.
10. Belkhiri A., Dar A.A., Zaika A., Kelley M., El-Rifai W. t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 2008, 68:395-403.
11. Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 2000, 485:87-93.
12. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
13. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. JBiol Chem 2001, 276:37436-37442.
14. Birch N.W., Zeleznik-Le N.J. Glycogen synthase kinase-3 and leukemia: restoring the balance. Cancer Cell 2010, 17:529-531.
15. Boultwood J., Yip B.H., Vuppusetty C., Pellagatti A., Wainscoat J.S. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. Adv Biol Regul 2013, 53:8-17.
16. Braccini L., Ciraolo E., Martini M., Pirali T., Germena G., Rolfo K., et al. PI3K keeps the balance between metabolism and cancer. Adv Biol Regul 2012, 52:389-405.
17. Bradshaw R.A., Chalkley R.J., Biarc J., Burlingame A.L. Receptor tyrosine kinase signaling mechanisms: devolving TrkA responses with phosphoproteomics. Adv Biol Regul 2013, 53:87-96.
18. Burke J.E., Williams R.L. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul 2013, 53:97-110.
19. Burns K.A., Vanden Heuvel J.P. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007, 1771:952-960.
20. Calleja V., Laguerre M., Larijani B. Role of the C-terminal regulatory domain in the allosteric inhibition of PKB/Akt. Adv Biol Regul 2012, 52:46-57.
21. Carnevalli L.S., Trumpp A. Tuning mTORC1 activity for balanced self-renewal and differentiation. Dev Cell 2010, 19:187-188.
22. Chan C.B., Chen Y., Liu X., Papale L., Escayg A., Mei L., et al. Essential role of PIKE GTPases in neuronal protection against excitotoxic insults. Adv Biol Regul 2012, 52:66-76.
23. Chappell W.H., Abrams S.L., Stadelman K.M., LaHair M.M., Franklin R.A., Cocco L., et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Biol Regul 2013, 53:146-155.
24. Chen C., Liu Y., Liu R., Ikenoue T., Guan K.L., Liu Y., et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. JExp Med 2008, 205:2397-2408.
25. Cheung N., Chan L.C., Thompson A., Cleary M.L., So C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007, 9:1208-1215.
26. Clapham J.C., Arch J.R. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab 2007, 9:259-275.
27. Clarke J.H., Irvine R.F. The activity, evolution and association of phosphatidylinositol 5-phosphate 4-kinases. Adv Biol Regul 2012, 52:40-45.
28. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
29. Cole A., Frame S., Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004, 377:249-255.
30. Collins E.C., Rabbitts T.H. The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. Trends Mol Med 2002, 8:436-442.
31. Costoya J.A., Hobbs R.M., Barna M., Cattoretti G., Manova K., Sukhwani M., et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004, 36:653-659.
32. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
33. Dal Col J., Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle 2008, 7:2813-2816.
34. Davidson G., Wu W., Shen J., Bilic J., Fenger U., Stannek P., et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005, 438:867-872.
35. Del Barco S., Vazquez-Martin A., Cufi S., Oliveras-Ferraros C., Bosch-Barrera J., Joven J., et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011, 2:896-917.
36. del Ser T., Steinwachs K.C., Gertz H.J., Andrés M.V., Gómez-Carrillo B., Medina M., et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. Alzheimers Dis 2013, 33:205-215.
37. Dickson C., Fantl V., Gillett C., Brookes S., Bartek J., Smith R., et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995, 90:43-50.
38. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase- 3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
39. Ding Q., He X., Hsu J.M., Xia W., Chen C.T., Li L.Y., et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007, 27:4006-4017.
40. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. JCell Sci 2003, 116:1175-1186.
41. Doble B.W., Patel S., Wood G.A., Kockeritz L.K., Woodgett J.R. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007, 12:957-971.
42. Dong J., Peng J., Zhang H., Mondesire W.H., Jian W., Mills G.B., et al. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 2005, 65:1961-1972.
43. Doulatov S., Notta F., Rice K.L., Howell L., Zelent A., Licht J.D., et al. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev 2009, 23:2076-2087.
44. Elong Edimo W., Vanderwinden J.M., Erneux C. SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. Adv Biol Regul 2013, 53:28-37.
45. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980, 107:519-527.
46. Espinosa L., Inglés-Esteve J., Aguilera C., Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. JBiol Chem 2003, 278:32227-32235.
47. Farago M., Dominguez I., Landesman-Bollag E., Xu X., Rosner A., Cardiff R.D., et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 2005, 65:5792-5801.
48. Ferkey D.M., Kimelman D. Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. JBiol Chem 2002, 277:16147-16152.
49. Follo M.Y., Faenza I., Fiume R., Ramazzotti G., McCubrey J.A., Martelli A.M., et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul 2012, 52:2-6.
50. Follo M.Y., Marmiroli S., Faenza I., Fiume R., Ramazzotti G., Martelli A.M., et al. Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. Adv Biol Regul 2013, 53:2-7.
51. Foltz D.R., Santiago M.C., Berechid B.E., Nye J.S. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 2002, 12:1006-1011.
52. Franca-Koh J., Yeo M., Fraser E., Young N., Dale T.C. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. JBiol Chem 2002, 277:43844-43848.
53. Fu Y., Hu D., Qiu J., Xie X., Ye F., Lu W.G. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Internl J Gyn Cancer 2011, 21:439-444.
54. Gan B., Sahin E., Jiang S., Sanchez-Aguilera A., Scott K.L., Chin L., et al. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA 2008, 105:19384-19389.
55. Gan B., Hu J., Jiang S., Liu Y., Sahin E., Zhuang L., et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010, 468:701-704.
56. Gao C., Holscher C., Liu Y., Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosciences 2012, 23:1-11.
57. Gery S., Park D.J., Vuong P.T., Virk R.K., Muller C.I., Hofmann W.K., et al. RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp Hematol 2007, 35:572-578.
58. Gil D., Ciolczyk-Wierzbicka D., Dulinska-Litewka J., Zwawa K., McCubrey J.A., Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial mesenchymal transition. Adv Enzym Regul 2011, 51:195-207.
59. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-1817.
60. Grimaldi C., Chiarini F., Tabellini G., Ricci F., Tazzari P.L., Battistelli M., et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012, 26:91-100.
61. Gupta K., Gulen F., Sun L., Aguilera R., Chakrabarti A., Kiselar J., et al. GSK3 is a regulator of RAR-mediated differentiation. Leukemia 2012, 26:1277-1285.
62. Habib S.L. Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells. Oncotarget 2011, 2:958-959.
63. Han X., Ju J.H., Shin I. Glycogen synthase kinase 3-beta phosphorylates novel S/T-P-S/T domains in Notch1 intracellular domain and induces its nuclear localization. Biochem Biophys Res Commun 2012, 423:282-288.
64. Hartigan J.A., Xiong W.C., Johnson G.V. Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun 2001, 284:485-489.
65. Hausmann J., Perrakis A., Moolenaar W.H. Structure-function relationships of autotaxin, a secreted lysophospholipase D. Adv Biol Regul 2013, 53:112-117.
66. He L.Z., Bhaumik M., Tribioli C., Rego E.M., Ivins S., Zelent A., et al. Two critical hits for promyelocytic leukemia. Mol Cell 2000, 6:1131-1141.
67. Hnia K., Kretz C., Amoasii L., Bohm J., Liu X., Messaddeq N., et al. Primary T-tubule and autophagy defects in the phosphoinositide phosphatase Jumpy/MTMR14 knockout mice muscle. Adv Biol Regul 2012, 52:98-107.
68. Hobbs R.M., Seandel M., Falciatori I., Rafii S., Pandolfi P.P. Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell 2010, 142:468-479.
69. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
70. Huang J., Zhang Y., Bersenev A., O'Brien W.T., Tong W., Emerson S.G., et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. JClin Invest 2009, 119:3519-3529.
71. Huang J., Nguyen-McCarty M., Hexner E.O., Danet-Desnoyers G., Klein P.S. Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med 2012, 18:1778-1785.
72. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993, 12:803-808.
73. Hunt T. On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis. Adv Biol Regul 2013, 2013(53):173-178.
74. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998, 17:1371-1384.
75. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
76. Inoki K., Kim J., Guan K.L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012, 52:381-400.
77. Ito K., Carracedo A., Weiss D., Arai F., Ala U., Avigan D.E., et al. APML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012, 18:1350-1358.
78. Jang H.J., Yang Y.R., Kim J.K., Choi J.H., Seo Y.K., Lee Y.H., et al. Phospholipase C-1 involved in brain disorders. Adv Biol Regul 2013, 53:51-62.
79. Jeannet G., Scheller M., Scarpellino L., Duboux S., Gardiol N., Back J., et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 2008, 111:142-149.
80. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. Adv Biol Regul 2013, 53:202-210.
81. Jin Y.H., Kim H., Ki H., Yang I., Yang N., Lee K.Y., et al. Beta-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. Biochim Biophys Acta 2009, 1793:290-299.
82. Jin Y.H., Kim H., Oh M., Ki H., Kim K. Regulation of Notch1/NICD and Hes1 expressions by GSK-3alpha/beta. Mol Cells 2009, 27:15-19.
83. Kaidanovich-Beilin O., Lipina T.V., Takao K., van Eede M., Hattori S., Laliberté C., et al. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2009, 2:35.
84. Kanaho Y., Unoki T. Regulation and functions of the lipid kinase PIP5K g661 at synapses. Adv Biol Regul 2012, 52:59-65.
85. Katiyar S., Liu E., Knutzen C.A., Lang E.S., Lombardo C.R., Sankar S., et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep 2009, 10:866-872.
86. Kawazoe H., Bilim V.N., Ugolkov A.V., Yuuki K., Naito S., Nagaoka A., et al. GSK-3 inhibition invitro and invivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun 2012, 423:490-495.
87. Keune W.J., Jones D.R., Divecha N. PtdIns5P and Pin1 in oxidative stress signaling. Adv Biol Regul 2013, 53:179-189.
88. Kim E.K., Yun S.J., Ha J.M., Kim Y.W., Jin I.H., Woo D.H., et al. Loss of Akt1 evokes epithelial-mesenchymal transition by autocrine regulation of transforming growth factor-1. Adv Biol Regul 2012, 52:88-96.
89. Kise Y., Morinaka A., Teglund S., Miki H. Sufu recruits GSK3beta for efficient processing of Gli3. Biochem Biophys Res Commun 2009, 387:569-574.
90. Kogerman P., Grimm T., Kogerman L., Krause D., Undén A.B., Sandstedt B., et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol 1999, 1:312-319.
91. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
92. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998, 17:3714-3725.
93. Leslie N.R., Dixon M.J., Schenning M., Gray A., Batty I.H. Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Adv Biol Regul 2012, 52:205-213.
94. Lesort M., Jope R.S., Johnson G.V. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. JNeurochem 1999, 72:576-584.
95. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000, 97:4262-4266.
96. Linseman D.A., Butts B.D., Precht T.A., Phelps R.A., Le S.S., Laessig T.A., et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. JNeuroscience 2004, 24:9993-10002.
97. Luna-Medina R., Cortes-Canteli M., Sanchez-Galiano S., Morales-Garcia J.A., Martinez A., Santos A., et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. JNeurosci 2007, 27:5766-5776.
98. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009, 273:194-200.
99. Ma C., Wang J., Gao Y., Gao T.W., Chen G., Bower K.A., et al. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007, 67:7756-7764.
100. MacAulay K., Doble B.W., Patel S., Hansotia T., Sinclair E.M., Drucker D.J., et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007, 6:329-337.
101. Maccario H., Perera N.M., Davidson L., Downes C.P., Leslie N.R. PTEN is destabilized by phosphorylation on Thr366. Biochem J 2007, 405:439-444.
102. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
103. Majeti R., Becker M.W., Tian Q., Lee T.L., Yan X., Liu R., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009, 106:3396-3401.
104. Major M.B., Camp N.D., Berndt J.D., Yi X., Goldenberg S.J., Hubbert C., et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007, 316:1043-1046.
105. Marchand B., Tremblay I., Cagnol S., Boucher M.J. Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 2012, 33:529-537.
106. Martelli A.M., Chiarini F., Evangelisti C., Ognibene A., Bressanin D., Billi A.M., et al. Targeting the liver Kinase B1/AMP-dependent kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Therap Targets 2012, 6:729-742.
107. Martelli A.M., Tabellini G., Ricci F., Evangelisti C., Chiarini F., Bortul R., et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Adv Biol Regul 2012, 52:214-227.
108. McCubrey J.A., Chappell W.H., Abrams S.L., Franklin R.A., Long J.M., Sattler J.A., et al. Targeting the cancer initiating cells: the Achilles' heel of cancer. Adv Enzym Regul 2011, 51:152-162.
109. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012, 3:954-987.
110. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Franklin R.A., Montalto G., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012, 3:1068-1111.
111. McCubrey J.A., Abrams S.L., Umezawa K., Cocco L., Martelli A.M., Franklin R.A., et al. Novel approaches to target cancer initiating cells-Eliminating the root of the cancer. Adv Biol Regul 2012, 52:249-264.
112. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2013 Jun 19, 10.1038/leu.2013.184.
113. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer?. Mo Cancer 2010, 9:144.
114. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
115. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005, 65:2076-2081.
116. Patel S., Woodgett J.R. Glycogen synthase kinase-3 and cancer: good cop, bad cop?. Cancer Cell 2008, 14:351-353.
117. Pouillon V., Marechal Y., Frippiat C., Erneux C., Schurmans S. Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells. Adv Biol Regul 2013, 53:39-50.
118. Putney J.W., Tomita T. Phospholipase C signaling and calcium influx. Adv Biol Regul 2012, 52:152-164.
119. Pyne N.J., Tonelli F., Lim K.G., Long J., Edwards J., Pyne S. Targeting sphingosine kinase 1 in cancer. Adv Biol Regul 2012, 52:31-38.
120. Raimondi C., Falasca M. Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv Biol Regul 2012, 52:166-182.
121. Ribeiro D., Melao A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013, 53:211-222.
122. Rice K.L., Licht J.D. Hox deregulation in acute myeloid leukemia. Clin Invest 2007, 117:865-868.
123. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer. Cell 2008, 132:681-696.
124. Rossig L., Badorff C., Holzmann Y., Zeiher A.M., Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. JBiol Chem 2002, 277:9684-9689.
125. Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S. Polakis. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996, 272:1023-1026.
126. Rynkiewicz N.K., Liu H.J., Balamatsias D., Mitchell C.A. INPP4A/INPP4B and P-Rex proteins: related but different?. Adv Biol Regul 2012, 52:265-279.
127. Saldivar J.C., Bene J., Hosseini S.A., Miuma S., Horton S., Heerema N.A., et al. Characterization of the role of Fhit in suppression of DNA damage. Adv Biol Regul 2013, 53:77-85.
128. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004, 10:55-63.
129. Sayas C.L., Ariaens A., Ponsioen B., Moolenaar W.H. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell 2006, 17:1834-1844.
130. Shakoori A., Ougolkov A., Yu Z.W., Zhang B., Modarressi M.H., Billadeau D.D., et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005, 334:1365-1373.
131. Shears S.B., Weaver J.D., Wang H. Structural insight into inositol pyrophosphate turnover. Adv Biol Regul 2013, 53:19-27.
132. Shiizaki S., Naguro I., Ichijo H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul 2013, 53:135-144.
133. Shimura T. Acquired radioresistance of cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. JRadiation Res 2011, 52:539-544.
134. Shin S., Wolgamott L., Yu Y., Blenis J., Yoon S.O. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011, 108:1204-1213.
135. Shin S., Wolgamott L., Yoon S.O. Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1). Cell Cycle 2012, 11:1053-1054.
136. Shirai Y., Ikeda M., Saito N. Regulation of diacylglycerol kinase by phosphorylation. Adv Biol Regul 2012, 52:239-247.
137. So C.W., Karsunky H., Passegué E., Cozzio A., Weissman I.L., Cleary M.L. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 2003, 3:161-171.
138. Song J., Park S., Kim M., Shin I. Down-regulation of Notch-dependent transcription by Akt invitro. FEBS Lett 2008, 582:1693-1699.
139. Stambolic V., Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 1994, 303:701-704.
140. Stein R.S., Vogler W.R., Lefante J. Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia. A Southeastern Cancer Study Group study. Am J Clin Oncol 1984, 7:365-369.
141. Sutherland C. What are the bona fide GSK3 substrates?. Int J Alzheimer's Dis 2011, 23. Article ID 505607.
142. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993, 296:15-19.
143. Takenaka K., Kise Y., Miki H. GSK3beta positively regulates Hedgehog signaling through Sufu in mammalian cells. Biochem Biophys Res Commun 2007, 353:501-508.
144. Tan J., Zhuang L., Leong H.S., Iyer N.G., Liu E.T., Yu Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 2005, 65:9012-9020.
145. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670.
146. Toker A. Achieving specificity in Akt signaling in cancer. Adv Biol Regul 2012, 52:78-87.
147. Tu-Sekine B., Goldschmidt H., Petro E., Raben D.M. Diacylglycerol kinase: regulation and stability. Adv Biol Regul 2013, 53:118-126.
148. Tullai J.W., Graham J.R., Cooper G.M. AGSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells. Cell Cycle 2011, 10:3072-3077.
149. Vadysirisack D.D., Baenke F., Ory B., Lei K., Ellisen L.W. Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol 2011, 31:4356-4365.
150. Vakana E., Platanias L.C. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011, 2:1322-1328.
151. van der Vos K.E., Gomez-Puerto C., Coffer P.J. Regulation of autophagy by Forkhead box (FOX) O transcription factors. Adv Biol Regul 2012, 52:122-136.
152. van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. JBiol Chem 2002, 277:17901-17905.
153. Wang Y., Lam J.B., Lam K.S., Liu J., Lam M.C., Hoo R.L., et al. Adiponectin modulates the glycogen synthase kinase-3beta/betacatenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006, 66:11462-11470.
154. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C., Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
155. Wang Z., Iwasaki M., Ficara F., Lin C., Matheny C., Wong S.H., et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010, 17:597-608.
156. Wang H., Brown J., Gu Z., Garcia C.A., Liang R., Alard P., et al. Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. JImmunol 2011, 186:5217-5226.
157. Welcker M., Singer J., Loeb K.R., Grim J., Bloecher A., Gurien-West M., et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003, 12:381-392.
158. Wilson A., Laurenti E., Oser G., van der Wath R.C., Blanco-Bose W., Jaworski M., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135:1118-1129.
159. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990, 9:2431-2438.
160. Wu D., Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2010, 35:161-168.
161. Yang Y.R., Choi J.H., Chang J.S., Kwon H.M., Jang H.J., Ryu S.H., et al. Diverse cellular and physiological roles of phospholipase C-1. Adv Biol Regul 2012, 52:138-151.
162. Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18:606-618.
163. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
164. Zaidi S.K., Trombly D.J., Dowdy C.R., Lian J.B., Stein J.L., van Wijnen A.J., et al. Epigenetic mechanisms in leukemia. Adv Biol Regul 2012, 52:369-376.
165. Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., et al. Adual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005, 438:873-877.
166. Zeng X., Huang H., Tamai K., Zhang X., Harada Y., Yokota C., et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008, 135:367-375.
167. Zhao Y., Altman B.J., Coloff J.L., Herman C.E., Jacobs S.R., Wieman H.L., et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 2007, 27:4328-4339.
168. Zhou F., Zhang L., van Laar T., van Dam H., Ten Dijke P. GSK3beta inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 2011, 22:3533-3540.
169. Zhou W., Wang L., Gou S.M., Wang T.L., Zhang M., Liu T., et al. shRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Lett 2012, 316:178-186.
170. Zou J., Majerus P.W., Wilson D.B., Schrade A., Chang S.C., Wilson M.P. The role of myotubularin-related phosphatases in the control of autophagy and programmed cell death. Adv Biol Regul 2012, 52:282-289.